Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952610 · ClinicalTrials.gov registry record · Phase 3
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
A Phase 3 study, sponsored by Milestone Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT04952610 is a Phase 3 study that has completed, run by Milestone Pharmaceuticals. The registered enrollment target is 130 participants.
The verdict
NCT04952610, a Phase 3 study, has completed, sponsored by Milestone Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any significant safety issues during participation period in a previous clinical trial of etripamil NS, as per Investigator's assessment , are excluded. This study will be conducted by Investigators who previously participated in a Milestone Pharmaceuticals clinical trial and are trained on the use of etripamil NS.
Interventions
- DRUG Etripamil NS 70 mg
- DEVICE Aptar Pharma Nasal Spray Bidose System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2026-04-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04952610
The ClinicalTrials.gov registry entry for NCT04952610 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milestone Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etripamil NS 70 mg is the first listed.
NCT04952610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04952610 about?
NCT04952610 is a clinical study titled "Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia". This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any sig...
What is the current status of trial NCT04952610?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2021-12-13. Estimated completion is 2026-04-10.
What interventions are being tested in trial NCT04952610?
The interventions under investigation include: Etripamil NS 70 mg (DRUG), Aptar Pharma Nasal Spray Bidose System (DEVICE).
Who is sponsoring clinical trial NCT04952610?
This trial is sponsored by Milestone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.